Fondazione Policlinico Universitario Agostino Gemelli IRCCS
policlinicogemelli.itLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
915
Active
474
Phase 3
11
Total enrollment
1,159,164
Pipeline matrix
Showing 40 of 80 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Anticoagulant | — | — | — | — | 2 | ||
| Platinum + Gemcitabine | — | — | — | — | — | 1 | |
| Avelumab first-line maintenance | — | — | — | — | — | 1 | |
| Medical therapy | — | — | — | — | — | 1 | |
| Antiplatelet Drug | — | — | — | — | — | 1 | |
| Statin | — | — | — | — | — | 1 | |
| Beta blocker | — | — | — | — | — | 1 | |
| ACEi/ARB | — | — | — | — | — | 1 | |
| CCB | — | — | — | — | — | 1 | |
| Nitrates | — | — | — | — | — | 1 | |
| Rituximab | — | — | — | — | — | 1 | |
| Standard systemic therapy (chemotherapy) without RT/SBRT | — | — | — | — | — | 1 | |
| Nivolumab | — | — | — | — | 2 | ||
| donor FMT | — | — | — | — | — | 2 | |
| Donor - FMT | — | — | — | — | — | 1 | |
| Organoid-guided treatment | — | — | — | — | — | 1 | |
| Bleomicina | — | — | — | — | — | 1 | |
| Nab paclitaxel | — | — | — | — | — | 1 | |
| Cisplatin | — | — | — | — | — | 1 | |
| single FMT | — | — | — | — | — | 1 | |
| sequential FMT | — | — | — | — | — | 1 | |
| FMT | — | — | — | — | — | 1 | |
| CAR T cell | — | — | — | — | — | 1 | |
| encorafenib + cetuximab + FOLFIRI | — | — | — | — | — | 1 | |
| CDK4/6 Inhibitor | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | 5 | |||
| Pembrolizumab | — | — | — | — | 4 | ||
| Paclitaxel | — | — | — | 4 | |||
| Osimertinib | — | — | — | — | 2 | ||
| Whole Exome Sequencing | — | — | — | — | — | 1 | |
| advanced sistemic therapies | — | — | — | — | — | 1 | |
| Hospital-Based Vaccination Pathway | — | — | — | — | — | 1 | |
| Genetic profiling of all eligible patients | — | — | — | — | — | 1 | |
| Evaluation of HS1,2 polymorphisms | — | — | — | — | — | 1 | |
| PRS | — | — | — | — | — | 1 | |
| Intravenous iron | — | — | — | — | — | 1 | |
| Sideral Folico | — | — | — | — | — | 1 | |
| Diagnostic Test | — | — | — | — | — | 1 | |
| DOACs | — | — | — | — | — | 1 | |
| Illumina Infinium Global Screening Array 4.0 | — | — | — | — | — | 1 |
40 more active programs hidden
Next readouts
- 2022-12-31
- 2023-04-01
- 2023-05-01
- 2024-09-29
- 2025-03-31
- 2025-06-15
- 2025-06-30
- 2025-07
- 2025-07-31
- 2025-10
Top conditions
- Ovarian Cancer25
- Breast Cancer20
- Gynecologic Cancer14
- Obesity13
- Endometrial Cancer12
- Parkinson Disease12
- COVID-1911
- Cervical Cancer9
Frequently asked questions about Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- How many clinical trials does Fondazione Policlinico Universitario Agostino Gemelli IRCCS have on ClinicalTrials.gov?
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS is listed as the lead sponsor on 915 clinical trials in ClinicalTrials.gov, 474 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Fondazione Policlinico Universitario Agostino Gemelli IRCCS's trials are in Phase 3?
- 11 of Fondazione Policlinico Universitario Agostino Gemelli IRCCS's trials are in Phase 3, spread across 80 active drug programs.
- What therapeutic areas does Fondazione Policlinico Universitario Agostino Gemelli IRCCS focus on?
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS's most-studied conditions on ClinicalTrials.gov are Ovarian Cancer, Breast Cancer, Gynecologic Cancer, Obesity, Endometrial Cancer.
- When are Fondazione Policlinico Universitario Agostino Gemelli IRCCS's next clinical trial readouts?
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS has 10 upcoming primary-completion readouts tracked here; the soonest is “An Integrated Genomic Approach to Assess Genetic Risk and Drug Sensitivity”, expected around 2022-12-31.